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Abstract
The use of ketamine infusion for sedation/analgesia in patients receiving
extracorporeal membrane oxygenation (ECMO) therapy has not been
described. The aims of this retrospective cohort study were to explore whether
ketamine infusion for patients requiring ECMO therapy was associated with
altered RASS scores, decreased concurrent sedative or opioid use, or with
changes in vasopressor requirements. 
All patients on ECMO who received ketamine infusions in addition to sedative
and/or opioid infusions between December 2013 and October 2014 at
Barnes-Jewish Hospital in St. Louis were retrospectively identified. Patient
characteristics and process of care data were collected.
A total of 26 ECMO patients receiving ketamine infusion were identified. The
median (inter quartile range [range]) age was 40 years (30-52 [25-66]) with
62% male. The median starting infusion rate of ketamine was 50 mg/hr (30-50
[6-150]) and it was continued for a median duration of 9 days (4-14 [0.2-21]).
Prior to ketamine, 14/26 patients were receiving vasopressor infusions to
maintain hemodynamic stability. Ketamine initiation was associated with a
decrease in vasopressor requirement in 11/26  patients within two hours, and
0/26 required an increase (p<0.001). All patients were receiving sedative
and/or opioid infusions at the time of ketamine initiation; 9/26 had a decrease in
these infusions within two hours of ketamine initiation, and 1/26 had an
increase (p=0.02; odds ratio for decrease to increase = 9; 95% CI, 1.14 to
71.04). The median (IQR[range]) RASS score 24 hours before ketamine
initiation was -4 (-3 to -5, [0 to -5]) and after ketamine was -4 (-3 to -4 [-1 to -5]) (
 = 0.614).P
Ketamine infusion can be used as an adjunctive sedative agent in patients
receiving ECMO and may decrease concurrent sedative and/or opioid infusions
without altering RASS scores. The hemodynamic effects of ketamine may
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Introduction
Continuous infusion of sedatives and opioids are commonly 
employed to alleviate pain, agitation, and anxiety in critically ill 
patients admitted to the intensive care unit1–2. Significant vari-
ability in sedation practices exist nationwide in the United States3, 
and efforts have been made to investigate systematic approaches 
to sedation management in order to improve patient outcomes4. 
As the adverse effects of over-sedation and prolonged sedation 
have become more apparent (e.g. longer duration of mechanical 
ventilation, longer ICU length of stay, increased mortality)5–7, the 
paradigm has shifted towards a “more is less” strategy8. Keeping 
critically ill patients less sedated and more interactive is supported by 
recent clinical practice guidelines on pain, agitation, and delirium9. 
However, severe agitation is common in critically ill patients and 
may have many underlying causes; agitation in such patients is 
associated with prolonged ventilator and ICU days as well as higher 
rates of self-extubation10. It is therefore important to determine the 
optimum level of sedation for every individual critically ill patient. 
Patients requiring extracorporeal membrane oxygenation (ECMO) 
therapy typically require sedation during the acute phase of their 
illness or when they are agitated such that they are at risk for self-
harm, such as displacement of ECMO tubing. However, patients 
receiving ECMO support are challenging to sedate, often require 
escalating doses of sedatives and opioids to maintain an appropriate, 
safe level of sedation11. The challenges often relate to the dynamic 
alterations in pharmacokinetic (PK) and pharmacodynamic (PD) 
properties of commonly used sedatives and opioids in the setting of 
ECMO. Hemodilution, protein binding changes, changes in blood 
flow especially through the lungs, sequestration of medications by 
the ECMO circuit, binding of drugs to the oxygenator membrane, 
and organ function changes may impact the clinical effects of seda-
tive and analgesic medications in this patient population10–19.
Ketamine is potentially a promising complementary sedative agent 
in the setting of ECMO in that it has hypnotic, analgesic, and amne-
sic properties owing to its activity at a variety of receptors. Ketamine 
is an antagonist of glutamate receptors as well as N-methyl-D-aspar-
tate (NMDA) receptors and it has activity at all opioid receptors, 
though with different affinities and activities at those receptors. Ket-
amine also antagonizes nicotinic acetylcholine receptors noncom-
petitively and profoundly inhibits muscarinic receptors in addition 
to inhibiting L-type calcium channels20. Ketamine’s lack of respira-
tory depression, bronchodilating properties, in addition to generally 
being well tolerated hemodynamically (despite some myocardial 
depressant properties) theoretically make it an attractive choice for 
sedation and analgesia21. Recent clinical practice guidelines on pain, 
agitation, and delirium9 mention the use of ketamine as a possible 
adjunct for non-neuropathic pain management and suggest that non-
benzodiazepine sedatives such as propofol and dexmedetomidine 
may be preferred over benzodiazepine sedation. They do not pro-
vide recommendations for ketamine use as a continuous infusion. 
To our knowledge, no studies have compared clinical outcomes in 
ICU patients sedated with ketamine infusion to other agents. Ket-
amine may provide an alternative or adjunct option in difficult to 
sedate patients. As critical drug shortages continue to impact the 
selection of available drugs (e.g. propofol shortage22), it is impor-
tant to review all relevant agents available for clinical use. The 
purpose of this study was to describe the use of ketamine infusion 
for patients receiving concurrent sedation/analgesia on ECMO sup-
port. The specific aims were to determine whether ketamine altered 
Richmond Agitation Sedation Scale (RASS) scores or decreased 
concurrent sedative, opioid, or vasopressor requirements.
Methods
The Washington University School of Medicine Human Research 
Protection Office and the Protocol Review and Monitoring Com-
mittee approved this study (IRB # 201409142). This case series 
was conducted at Barnes-Jewish Hospital, a 1,250 bed urban teach-
ing hospital affiliated with the Washington University School of 
Medicine in St. Louis, MO, between December 2013 and October 
2014. All patients on ECMO support receiving ketamine infusion in 
addition to sedative and/or opioid infusions during the study period 
were retrospectively identified via an informatics query. There were 
no exclusion criteria. Patient characteristics, medical and surgical 
history, as well as process of care data were collected from elec-
tronic medical records. All ECMO patients are cared for in a single 
cardiothoracic intensive care unit. Doses and durations of all infu-
sions of sedatives, opioids and vasopressor agents documented as 
administered during ketamine administration were collected. All 
available RASS scores charted 24 hours before and after ketamine 
initiation were collected on each patient. Statistical analysis was 
completed by using the SPSS software, version 18.0 (SPSS, Inc., 
Chicago, IL). Descriptive statistics were used to analyze the data 
collected. The median RASS scores as well as the median nore-
pinephrine infusion rates (in patients who were receiving norepine-
phrine) before and after ketamine initiation were compared with a 
Wilcoxon signed-rank test. The McNemar test was used to assess 
whether or not a significant proportion of patients had a clinically 
meaningful increase or decrease in the dose of sedative, analgesic 
or vasopressor infusions two hours after ketamine initiation. Based 
on consensus of the investigators, the following minimum changes 
were arbitrarily pre-specified as clinically meaningful for sedative, 
analgesic and vasopressor infusions: propofol, 10 mcg/kg/min; mida-
zolam, 1 mg/hour; dexmedetomidine, 0.2 mcg/kg/hour; fentanyl, 
25 mcg/hour; norepinephrine 0.02 mcg/kg/min; and vasopressin 
0.02 units/min.
Results
Dataset 1. Ketamine infusion for sedation and analgesia data for 
patients receiving extracorporeal membrane oxygenation support
http://dx.doi.org/10.7910/DVN/28617
Dataset 1_Patient demographics of patients receiving ketamine 
infusions while on extracorporeal membrane oxygenation therapy. 
Dataset 2_Continuous infusion details of patients receiving 
ketamine infusions while on extracorporeal membrane oxygenation 
therapy. Dataset 3_Vasopressor and sedative/opioid changes 
of patients receiving ketamine infusions while on extracorporeal 
membrane oxygenation therapy. Dataset 4_RASS scores before 
and after ketamine of patients receiving ketamine infusions while on 
extracorporeal membrane oxygenation therapy.
A total of 26 ECMO patients receiving ketamine infusion were 
identified. The median (inter quartile range [range]) patient age 
was 40 years (30–52 [25–66]) with 62% male. The most frequent 
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indication for ECMO support was respiratory failure associated 
with H1N1 influenza (46%). The median starting infusion rate of 
ketamine was 50 mg/hr (30–50 [6–150]) and it was continued for a 
median duration of 9 days (4–14 [0.2–21]). If the patient died in the 
hospital, that was considered the end of hospital stay. The median 
time from ECMO placement to ketamine initiation was 6 days (2–9 
[0.9–22]). Nine patients (35%) died during their hospital stay. The 
most common causes of death were cardiopulmonary arrest and res-
piratory failure (Table 1).
All patients were on a combination of one or more of the following 
agents: fentanyl, midazolam, propofol, and/or dexmedetomidine. At 
the time of ketamine initiation the median concurrent infusion rates 
of fentanyl (n=25), midazolam (n=19), propofol (n=10), and dexme-
detomidine (n=9) were 200 mcg/hr (150–450 [50–900]), 7 mg/hr 
(4–9 [1–15]), 40 mcg/kg/min (23–48 [10–100]), and 1.2 mcg/kg/hr 
(1–1.4 [0.6–1.5]), respectively. The median starting infusion rate of 
ketamine was 50 mg/hr (30–50 [6–150]) and continued for a median 
Table 1. Demographic data.
Characteristic n = 26
Age, median (IQR, range), y 41 (30–52, 25–66)
Male sex 16 (62)
Body weight, median (IQR, 
range), kg 91 (72–111, 41–167)
Type of ECMO
  VV alone 14 (54)
  VV and VA 7 (27)
  VA alone 5 (19)
Comorbidities
  Systolic heart failure 8 (31)
  Hypertension 9 (35)
  Atrial Fibrillation 7 (27)
  Diabetes mellitus 6 (23)
  Coronary artery disease 5 (19)
Hospital admitting diagnosis (not 
necessarily indication for ECMO 
support)
  H1N1 12 (46)
  Cardiogenic shock 4 (15)
  Acute respiratory distress 
syndrome 3 (12)
  Decompensated heart failure 3 (12)
  Other* 4 (15)




Hospital length of stay, median 
(IQR, range), d 
Mortality during hospital stay£ 
50 (26–69, 3.6–170) 
9 (35)
Values are expressed as n (%) unless specified otherwise.
ECMO = extracorporeal membrane oxygenation; VV = veno-
venous; VA = veno-arterial; IQR = interquartile range
*Other = leukemia, Stiffman syndrome, cystic fibrosis, pneumonia
£Cause of death documented in death summary note = 
cardiopulmonary arrest (2), respiratory failure (3), cardiogenic 
shock (2), acute respiratory distress syndrome (1), 
Hemophagocytic lymphohistiocytosis (1)
Table 2. Continuous infusions.
Continuous Infusion n = 26
Ketamine, n (%) 26 (100)
  Duration of infusion, d 9 (4–14, 0.2–21)
  Initial rate, mg/hr 50 (30–50, 6–150)
  Maximum rate, mg/hr 150 (65–250, 10–300)
  Minimum rate, mg/hr 50 (30–50, 6–150)
Fentanyl, n (%) 25 (96)
  Rate when ketamine 
initiated, mcg/hr 200 (150–400, 50–900)
  Maximum rate, mcg/hr 500 (200–600, 100–900)
  Minimum rate, mcg/hr 200 (100–350, 50–600)
Midazolam, n (%) 19 (73)
  Rate when ketamine 
initiated, mg/hr 7 (4–9, 1–15)
  Maximum rate, mg/hr 10 (8–12, 2–20)
  Minimum rate, mg/hr 2 (2–6, 1–10)
Propofol, n (%) 10 (38)
  Rate when ketamine 
initiated, mcg/kg/min 40 (23–48, 10–100)
  Maximum rate, mcg/kg/min 30 (20–50, 15–100)
  Minimum rate, mcg/kg/min 20 (11–30, 0–100)
Dexedetomidine, n (%) 9 (35)
  Rate when ketamine 
initiated, mcg/kg/hr 1.2 (1–1.4, 0.6–1.5)
  Maximum rate, mcg/kg/hr 1(0.7–1.5, 0.6–1.5)
  Minimum rate, mcg/kg/hr 0.5 (0.07–1, 0–1.5)
Neuromuscular blocking 
agents, n (%) 6 (23)
Values are median (IQR, range), unless specified otherwise
IQR = interquartile range.
duration of 9 days (4–14 [0.2–21]). Of note, 6 patients were receiv-
ing concurrent neuromuscular blocking agents during ketamine 
infusion (Table 2).
Prior to ketamine, 14/26 patients were receiving vasopressor infu-
sions to maintain hemodynamic stability. Ketamine initiation was 
associated with a clinically meaningful decrease in vasopressor 
requirement in 11/26 patients within two hours, and 0/26 required 
an increase in this time period (p<0.001). In the 14 patients on nore-
pinephrine infusions, the median (IQR [range]) dose before keta-
mine initiation was 0.1 mcg/kg/min (0.04–0.19 [0.02–0.26]) and 
two hours after ketamine initiation was 0.06 mcg/kg/min (0.01–0.11 
[0–0.26]) (P=0.003). All patients were receiving sedative and/or opi-
oid infusions at the time of ketamine initiation; 9/26 had a clinically 
meaningful decrease in these infusions within two hours of ketamine 
initiation, and 1/26 had an increase (p=0.02; odds ratio for decrease 
to increase = 9; 95% CI, 1.14 to 71.04) (Table 3). The median RASS 
score 24 hours before ketamine initiation was -4 (-3 to -5, [0 to -5]) 
and after ketamine was -4 (-3 to -4 [-1 to -5]) (P=0.614).
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Discussion
ECMO has repeatedly shown to complicate sedation management 
and optimization in the ICU as the PK/PD of sedatives and opioids 
become altered11,12,14–18. Lorazepam, midazolam, diazepam, propo-
fol, and morphine have all been shown to be sequestered by ECMO 
circuits to some extent11,17,18, posing a challenge when faced with 
trying to provide appropriate sedation/analgesia. In an ex vivo study, 
lipophilic medications such as fentanyl and midazolam have been 
shown to sequester in the ECMO circuit resulting in significant loss, 
while morphine remained relatively stable18. A similar finding was 
shown by Shekar and collegaues11 who assessed sedation require-
ments in 30 patients receiving ECMO support. Significant increases 
in dosing requirements of midazolam and morphine were noted, 
with venovenous ECMO patients receiving higher sedative doses 
overall than patients on venoarterial ECMO. The effect of ECMO 
on the PK/PD and other drug properties of ketamine in patients on 
ECMO has not been studied.
Ketamine causes dissociation of the thalamus from the limbic cor-
tex, resulting in patients resembling a cataleptic state. Patients may 
be unable to respond to sensory stimulation, may have nystagmus, 
and are able to conserve laryngeal and corneal reflexes21. Keta-
mine has been shown to decrease opioid consumption in surgical 
patients23,24, and is typically used as a one-time administration for 
analgesia, anesthesia induction, or procedural sedation. In addition 
to these indications, in some of the ICUs at our institution ketamine 
infusion has been added for patients who have been difficult to 
sedate to a target RASS. The use of ketamine infusion has particu-
larly been adopted at our institution for patients requiring ECMO 
therapy, as these patients have anecdotally been difficult to sedate 
optimally. However, the safety and efficacy of ketamine for these 
patients has not been established.
The favorable hemodynamic and PK/PD profile that ketamine 
provides in patients not requiring ECMO therapy makes ketamine 
theoretically an attractive sedative agent generally for use in the 





















*Based on consensus of the investigators, the following minimum changes 
were arbitrarily pre-specified as clinically meaningful for sedative, analgesic 
and vasopressor infusions: propofol, 10 mcg/kg/min; midazolam, 1 mg/hour; 
dexmedetomidine, 0.2 mcg/kg/hour; fentanyl, 25 mcg/hour; norepinephrine 
0.02 mcg/kg/min; and vasopressin 0.02 units/min.
ICU. The onset of action after IV administration occurs within 30 
seconds, with a maximum effect in about 1 minute. The distribu-
tion half-life is 5–10 minutes while the elimination half-life is 2–3 
hours, as ketamine undergoes extensive hepatic uptake and is pri-
marily excreted in the urine21,25. There are no dosing adjustments 
provided by the manufacturer in the presence of hepatic or renal 
dysfunction, however the optimal dose and duration of ketamine 
infusion for sedation remains unknown. Interestingly, in recent 
years neuroprotection, immune modulating, and antidepressant 
properties have also been suggested for ketamine26–28.
Ketamine’s lack of respiratory depression, bronchodilation proper-
ties and ability to increase blood pressure, heart rate, and cardiac 
output (although it does act as a myocardial depressant) further add 
to the attractive profile of this agent21,29. Interestingly, a decrease in 
vasopressor requirements with ketamine initiation was observed in 
many of the patients in this series. Although charted RASS scores 
before and during ketamine infusion did not change, a decrease in 
sedatives and/or opioids within two hours of ketamine initiation 
was more common than an increase in sedatives and/or opioids.
This study has several limitations. The small sample size, lack of 
blinding and retrospective design limit our ability to make causal 
inferences. Although the majority of patients receiving vasopres-
sors had a meaningful decrease in their requirements, we cannot 
exclude the fact that a decrease in vasopressors may have occurred 
unrelated to ketamine infusion. The observational design also lim-
its our ability to determine why certain drugs were chosen concur-
rently or why one was decreased prior to another. Although RASS 
values were collected, we were unable to determine the specified 
RASS goal for each patient. A RASS goal of 0 to -2 is targeted in 
most ICU patients, however 6 patients in this series were receiving 
neuromuscular blocking agents, rendering RASS values uninter-
pretable, while other patients received escalating doses of seda-
tives/opioids despite RASS values < -2. Furthermore, the use of a 
RASS score to monitor and guide sedation with ketamine has not 
been validated.
To our knowledge, this is the first study evaluating the use of keta-
mine infusion in patients on ECMO support. This study demon-
strated that ketamine infusion can be used as an adjunctive agent 
in patients receiving ECMO with possible sedative/opioid sparing 
effects. The cardiovascular properties may provide the hemody-
namic benefit of reducing vasopressor requirements. The lack of 
understanding related to optimizing pharmacotherapy in patients 
on ECMO has led to ongoing research, aimed at improving patient 
care13,19,30. All appropriate drugs should be considered in the absence 
of clear standards or guidelines for analgesia/sedation in patients 
receiving ECMO support. More rigorous study is warranted to fur-
ther investigate the suitability of ketamine for sedation in patients 
receiving ECMO support.
Data availability
Dataverse: Dataset 1. Ketamine infusion for sedation and analgesia 
data for patients receiving extracorporeal membrane oxygenation 
support, doi: 10.7910/DVN/2861731
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Summary:
The authors should be congratulated on an excellent article reporting an analysis of routinely collected
clinical data. They have addressed a clinically relevant subject and with an important research question
and a plausible and intuitive underlying hypothesis. Although retrospective, the study methodology is
good and the statistical analysis is appropriate. The results are clear, although the manner of presentation
could be improved. The discussion is informative and educational. The study limitations are appropriately
recognised and discussed, and suggestions for future investigation are made. The conclusions are well
supported by the data.
 
Abstract 
Clear and concise. It describes the background, results and the conclusions accurately.
Introduction
The introduction provides a clear and concise summary of the clinical background and relevance of the
study. The proposed hypothesis is clinically very relevant and plausible. The specific aims of the study are
stated clearly.
Methods
The description of the methods is completely clear. Appropriate methodology was applied. To assess the
influence of ketamine on sedative and vasopressor requirements, the authors arbitrarily chose, by
consensus, definitions of “ clinically meaningful minimal changes in medication after the start of ketamine
”.  This is a reasonable approach. The statistical analysis is clearly described and is appropriate. infusion
Results
We have two comments about the presentation of the results. The first is that table 2 is somewhat
confusing. It is not clear what the “maximum” and “minimum” infusion rates refer to. We suggest that the
authors clearly state the time period over which these maximum and minimum infusion rates were
determined. If these rates are not the rates after starting ketamine, then we suggest that the authors
present the median (IQR, range) infusion rates during some (arbitrary) time period after starting ketamine.
Our second comment about the results concerns the consistency of units used in presentation of sedative
and vasopressor infusion rates. In the methods the authors state arbitrarily chosen definitions of clinically
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meaningful changes in medication. These thresholds are defined in mcg/kg/min units for each of the
drugs. In the text and in table 2 of the results, the infusion rates of fentanyl and midazolam are reported in
different units (mcg/min). Thereafter the authors only report the numbers of patients in which there was a
clinically relevant change.  To more easily give the reader an idea of the magnitude of the relative
changes in infusion rate of fentanyl and midazolam, we suggest that for these drugs the before and
ketamine infusion rates are also presented in mcg/kg/min.
Discussion
Discussion is very well written and informative. The study limitations are well recognised. The conclusions
are supported by the data.
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This article is a retrospective case series reviewing the use of ketamine as an adjunctive sedative agent
for patients requiring ECMO support due to cardiopulmonary failure. The authors reviewed patient
characteristics including concurrent sedative, analgesic, and vasopressor infusion requirements as well
as RASS scores both before and after initiation of ketamine infusion. The authors defined what they
considered to be a 'clinically significant' changes in the doses of several agents including fentanyl,
midazolam, propofol, and norepinephrine. While the majority of patients had a 'clinically significant'
decrease in the doses of both vasopressors and other sedative/analgesic agents, these changes were
still quite small. The authors rightly note that they are not able to make a causal associations given the
retrospective nature of their data, but their inferences are sound based on pharmacologic and physiologic
principles. This case series demonstrates that ketamine appears to be an adjunctive agent that can safely
be used in patients on ECMO and may have the benefit of decreasing the requirements for other
sedatives and vasopressors, as well. This article is well-written and this topic warrants further
investigation in a prospective manner.
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